Iceland· IS-EU/1/24/1866/001
ELAHERE
A mirvetuximab soravtansine product containing mirvetuximab soravtansine, registered in Iceland by AbbVie Deutschland GmbH & Co. KG. The same ATC class is registered in 13 of our 19 countries.
Checked against Icelandic Medicines Agency (Iceland) on
Informational only — not a medical device.
Where it is registered
Mirvetuximab soravtansine is registered in 13 of 19 countries.
Countries holding a registration under ATC L01FX26 (mirvetuximab soravtansine), each read from that country’s own register.
- This record: Iceland, from Icelandic Medicines Agency (Iceland)
- 9 of them publish a price we can compare per daily dose
Mirvetuximab soravtansine · ATC L01FX26
13 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
Icelandic Medicines Agency (Iceland)- Active substance
- Mirvetuximab soravtansine
- Manufacturer
- AbbVie Deutschland GmbH & Co. KG
- Country
- Iceland (IS)
- ATC code
- L01FX26
- ATC class
- Mirvetuximab soravtansine
- Defined daily dose
- 18 mg, P
- Reimbursed
- Not published by this register
- Source register
- Icelandic Medicines Agency (Iceland)
- Last checked
- September 29, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Mirvetuximab soravtansine in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumElahere 5 mg/mlAbbVie Deutschland
- CzechiaELAHEREAbbVie Deutschland GmbH & Co.KG, Ludwigshafen
- FinlandELAHEREAbbVie Deutschland GmbH&Co.KG
- IrelandELAHERE 5 mg/mL concentrate for solution for infusionImmunogen Biopharma (Ireland) Limited
- NorwayElahereAbbVie Deutschland GmbH & Co
- PolandElahereAbbVie Deutschland GmbH & Co. KG
- SwedenELAHERE 5 mg/ml Koncentrat till infusionsvätska, lösningAbbVie Deutschland GmbH & Co KG
- SwitzerlandElahere
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- United Kingdom (Northern Ireland) · Elahere
- Liechtenstein · Elahere
- Norway · Elahere
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/043cd0cd-ff23-4691-b84b-6b71872ed556 GET /v1/drugs/043cd0cd-ff23-4691-b84b-6b71872ed556?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Innrennslisþykkni, lausn",
"source": "lyfjastofnun",
"atc_raw": "L01FX26",
"marketed": false,
"strength": "5 mg/ml",
"ma_number": "EU/1/24/1866/001",
"substance": "Mirvetuximab soravtansine",
"other_info": null,
"legal_status": "(R) Lyfseðilsskylt\r\n(H) Sjúkrahúsmerkt",
"ma_issued_serial": "45610"
}See everything about mirvetuximab soravtansine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.